US approves lower-cost twice-yearly injectable HIV prevention drug
The drug could widen access to prevention for people who find daily pills difficult to take consistently.
Tuesday 3 November · 18:01 · 1 min read
In 30 seconds
- The US Food and Drug Administration approved injectable lenacapavir for HIV prevention on November 2, 2026. [1]
- The medicine is given twice a year, and its expected price is about $40 per person per year. [1]
- The report says approval could help make the medicine available in more than 120 low- and middle-income countries. [1]
What happened
The US Food and Drug Administration approved injectable lenacapavir for HIV prevention on November 2, 2026, according to Fresh News. The medicine is given twice a year, and the report says its expected price is about $40 per person annually. The approval was described as a step toward distribution in more than 120 low- and middle-income countries.
Why it matters
A twice-yearly injection could be an alternative for people who have difficulty taking preventive pills every day. The report does not say whether or when the medicine will be available in Cambodia.
Background
The report says the expected annual price is close to the cost of preventive pills. It quotes a Unitaid official saying some people do not take daily pills as directed, which can leave them without protection.
Key terms
- HIV prevention
- Steps or medicines used to lower the chance of acquiring HIV.
- Low- and middle-income countries
- Countries grouped by their average income levels.
- Lenacapavir
- The name of the injectable medicine described in the report for HIV prevention.
Timeline
- November 2, 2026 The US Food and Drug Administration approved injectable lenacapavir for HIV prevention.
Sources (1)
[1] Fresh News សហរដ្ឋអាមេរិកអនុម័តថ្នាំបង្ការជំងឺអេដស៍ ចាក់ ២ដងក្នុងមួយឆ្នាំអស់ ៤០ដុល្លារ 3 Nov Read originalWas this explainer clear?
AI can make mistakes. Error reports go straight to our editors.
